Search

Amgen Inc

Lezárt

SzektorEgészségügy

414.71 1.86

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

405.01

Maximum

417.59

Fő mutatók

By Trading Economics

Bevétel

556M

2.4B

Értékesítés

1.4B

10B

P/E

Szektor átlag

25.03

47.946

Egy részvényre jutó nyereség

6.29

Osztalékhozam

2.43

Profit margin

23.622

Munkavállalók

31,500

EBITDA

-416M

3.4B

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

-0.61% downside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

2.43%

2.27%

Következő eredményjelentés

2026. nov. 3.

Következő osztalékfizetési dátum

2026. dec. 11.

Következő korábbi osztalék dátum

2026. nov. 20.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

13B

218B

Előző nyitás

412.85

Előző zárás

414.71

Hangulat hírek alapján

By Acuity

42%

58%

91 / 340 Rangsor szerint Healthcare

Amgen Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 9. 20:07 UTC

News
Correlated Moves

UBS analyst Michael Yee raised the price target on Amgen Inc to $470.00 from $430.00 while maintaining a Buy rating.

2026. okt. 8. 23:01 UTC

Amgen Inc shares are trading modestly higher in after-market hours, remaining above their 20-day moving average amid rising oil prices and inflation concerns.

2026. okt. 7. 23:11 UTC

Amgen Inc's shares declined slightly during after-market hours on Wednesday, following initial gains and positioning just below the regular session opening level.

2026. okt. 6. 23:15 UTC

Amgen Inc is trading modestly lower in after-market hours following a slight recovery earlier in the session, remaining in the middle of its one-month trading range.

2026. okt. 2. 20:07 UTC

Amgen Inc shares fell, continuing a downward trend with a cumulative drop since Thursday's close amid broader market declines.

2026. okt. 1. 23:05 UTC

Amgen Inc. is trading higher in after-market hours, despite a notable drop from an early high and marking its fourth consecutive session of lower closes.

2026. szept. 30. 23:40 UTC

Amgen Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and private sector job growth data.

2026. szept. 29. 20:07 UTC

News

Scotiabank raised Amgen's price target to $500 from $450, contributing to the stock's gains amid positive trial results for dazodalibep in systemic Sjögren's disease.

2026. szept. 28. 23:26 UTC

News

Amgen Inc's shares declined in after-market hours following the FDA's approval of Teva's Degevma, a biosimilar to Amgen's Xgeva, impacting its market position.

2026. szept. 24. 19:56 UTC

News

Amgen Inc shares are higher following positive topline results from its Phase 3 OASIZ 301 trial for dazodalibep in treating systemic Sjögren's disease.

2026. szept. 23. 23:41 UTC

Amgen Inc's shares are modestly higher in after-market trading, positioned near the midpoint of their one-month trading range.

2026. szept. 22. 20:01 UTC

Social Media
News

Amgen shares advanced as the company reported positive topline results from its Phase 3 OASIZ 301 study for Sjögren's disease, achieving its primary endpoint.

2026. szept. 21. 20:06 UTC

Amgen Inc is advancing today, continuing its upward trajectory since Friday's close, despite remaining below its 20-day moving average.

2026. szept. 18. 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

2026. szept. 17. 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

2026. szept. 16. 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

2026. szept. 15. 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

2026. szept. 14. 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

2026. szept. 11. 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

2026. szept. 10. 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

2026. szept. 8. 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

2026. szept. 4. 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

2026. szept. 3. 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2026. szept. 2. 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

2026. szept. 1. 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

2026. aug. 31. 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

2026. aug. 28. 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

2026. aug. 27. 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

2026. aug. 26. 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

2026. aug. 25. 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

Társak összehasonlítása

Árváltozás

Amgen Inc Előrejelzés

Célár

By TipRanks

-0.61% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 404.958 USD  -0.61%

Magas 500 USD

Alacsony 230 USD

27 Wall Street elemző 12 hónapos célárain alapulva a(z)Amgen Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

27 ratings

9

Vétel

16

Tartás

2

Eladás

Hangulat

By Acuity

91 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.